Loading
A small Rawalpindi study of CAR-T cells made in Pakistan and aimed at a protein on myeloma cells, for adults whose myeloma has come back after other treatment.
Registered as phase 2 on ClinicalTrials.gov (first posted 8 July 2026), a pilot, open-label, single-arm study of autologous BCMA-directed CAR-T cells in adults with relapsed or refractory multiple myeloma. The primary outcome is safety, tolerability and the feasibility of manufacturing and delivering the product. Estimated enrolment is 10, with primary completion estimated for 31 December 2027; the principal investigator listed is Tariq Ghafoor, at the National University of Medical Sciences clinical trial unit in Rawalpindi. No results are posted.
Shares Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Point-of-care and decentralised cell manufacturing, Cytokine release syndrome (CRS), CAR-T cell therapy.
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
Shares Point-of-care and decentralised cell manufacturing, BCMA, Cytokine release syndrome (CRS), CAR-T cell therapy.
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
Shares BCMA, Multiple myeloma.
Shares BCMA, CAR-T cell therapy, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/